|
|
|
Name
|
|
Consensus Report on the Use of Somatostatin Analogs for the Management of Neuroendocrine Tumors of the Gastropancreatic System
|
|
|
|
|
|
Manufacturer
|
|
Oxford University Press
|
|
|
|
|
|
SKU/Part Number
|
|
6016 ONC-6016 11/04
|
|
|
|
|
|
Brief Description
|
|
Authorized reprint from the Annals of Oncology, Volume 15, No. 6, 2004
|
|
|
|
|
|
Extended Description
|
|
K. Oberg; L. Kvols; M. Caplin; G. Delle Fave; W. de Herder; G. Rindi; P. Ruszniewski; E.A. Woltering & B. Wiedenmann.
This publication has been used by patients to help educate their medical professionals regarding the current course of treatment in using Somatostatin drug therapy.
This publication may also be downloaded from the webiste of the Carcinoid Cancer Foundation at www.carcinoid.org
Sections include: Critical Aspects of the pathology Report; Critical Aspects of Tumor Markers; Definitions of Functional & Non-Functional Digestive NETs; Which Markers Should be Used in the Clinic?; Imaging Modalitites Commonly Used in NETs; Surgical Considerations; Hepatic Arterial Cheoembolization; The Use of Interferon Treatment in NETs; The Role of Chemotherapy in Patients with NETs; Comments on the Roles of Chemotherapy in Different NETs; Therapy with Somatostain Analogs; Practical Aspects of Octreotide Therapy; When Should Somatostatin Analog Treatment be Started?; How Should Octreotide be Prescribed for Optimal Symptom Control; How Should a Patient on Somatostatin Analog Therapy be Followed?; What is the Role of SRS in the Follow-up of Patients with NETs?; What is the Role of Octreotide in Patients Receiving Radiolabled Somatostatin Therapy?; How Should Octreotide be Administered During Invasive Procedures; Do Patients with NETs Develop Drug Resistance; The Use of Octreotide for Paraneoplastic Syndromes; Are there Alternative Treatments when Octreotide Therapy Fails?
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
